Delirium Tremens, Hepatic Encephalopathy, and the Treacherous Mixed State: A Clinician's Guide to Differentiation and Treatment

 

GRAND ROUNDS REVIEW

Delirium Tremens, Hepatic Encephalopathy, and the Treacherous Mixed State: A Clinician's Guide to Differentiation and Treatment

Dr Neeraj Manikath , claude.ai

1. Clinical Introduction

 

🏥  Clinical Vignette •      A 48-year-old man with a background of alcohol use disorder (AUD) and Child–Pugh B cirrhosis is admitted via the emergency department following a witnessed generalised tonic-clonic seizure. His wife reports that he consumed approximately 180 g of alcohol daily until three days ago, when he abruptly stopped drinking after developing abdominal distension and jaundice. •      On arrival: GCS 12/15 (E3V4M5), temperature 38.6°C, heart rate 128 bpm, BP 168/96 mmHg, diaphoretic, tremulous. He is agitated and hallucinating — reporting insects on the wall. Examination reveals a flapping tremor (asterixis), scleral icterus, a moderately tender hepatomegaly, and shifting dullness. Labs show: ALT 214 U/L, bilirubin 84 μmol/L, albumin 26 g/L, INR 1.9, ammonia 92 μmol/L, sodium 128 mmol/L, and blood glucose 3.4 mmol/L. •      Is this delirium tremens? Hepatic encephalopathy? Or — most dangerously — both at once?

 

Alcohol use disorder affects over 280 million people worldwide, and approximately 5–10% of those who abruptly stop drinking will develop delirium tremens (DT) — the most severe form of alcohol withdrawal syndrome (AWS), carrying an untreated mortality of up to 37%. Yet for the large cohort of patients who also carry advanced liver disease, a second and equally life-threatening syndrome lurks: hepatic encephalopathy (HE). Crucially, both syndromes can coexist — the so-called "mixed state" — and misdiagnosis or mismanagement of either has lethal consequences. Benzodiazepines, the cornerstone of DT treatment, can precipitate or worsen HE. Conversely, withholding them in true DT out of fear of hepatic decompensation is equally dangerous. This review equips the clinician with the tools to navigate this diagnostic minefield.

 

2. Pathophysiology — Only What You Need at the Bedside

Delirium Tremens

Chronic alcohol use upregulates excitatory NMDA glutamate receptors and downregulates inhibitory GABA-A receptors — a neuroadaptive response to the sedating effects of alcohol. Abrupt cessation unmasks a state of CNS hyperexcitability: unchecked glutamatergic drive produces the clinical picture of agitation, tremor, seizures, autonomic storms, and hallucinations. The peak period of DT is 48–96 hours after the last drink, though onset up to 7–10 days is documented, particularly in hospitalised patients given inadvertent sedation.

Hepatic Encephalopathy

HE is fundamentally a neuroinflammatory disorder driven by systemic accumulation of gut-derived toxins — principally ammonia — through a failing hepatic filter. Hyperammonaemia causes astrocyte swelling (Alzheimer type II changes), impairs the blood-brain barrier, and augments GABAergic tone — paradoxically mimicking some features of AWS. Superimposed inflammation (infection, SIRS) dramatically amplifies the neurotoxic effect. Critically, ammonia alone does not explain all of HE; the gut microbiome, zinc deficiency, neurosteroids, and inflammatory cytokines all contribute.

The Mixed State — Why It Is So Dangerous

In patients with AUD and cirrhosis, both pathways operate simultaneously. The withdrawal-driven NMDA upregulation competes against the ammonia-driven GABA augmentation — producing a variable and clinically unpredictable phenotype. Autonomic instability (which in DT reflects withdrawal) may be masked by the haemodynamic vasodilation of portal hypertension. Seizures — a red flag for DT — may be absent because HE-driven GABAergic tone provides partial suppression. Treatment with benzodiazepines (BZDs) may initially improve DT features but paradoxically worsen encephalopathy. This is the most treacherous clinical scenario in alcohol-related liver disease.

 

3. Clinical Pearls 🪙

🪙  High-Yield Bedside Observations •      The timing of the last drink is everything — DT virtually never starts <6 hours after last drink; if delirium begins at presentation, think HE, sepsis, or Wernicke's first. •      Autonomic storm (HR >120, diaphoresis, hypertension, fever >38.5°C) strongly favours DT over HE. HE rarely causes sustained hypertension — if BP is high, treat DT. •      Asterixis (flapping tremor) is the hallmark of HE but can be subtle; always test both hands with wrists dorsiflexed and eyes closed for ≥15 seconds. Absence does not rule out HE. •      A normal ammonia does not exclude HE — specimen handling artefact is common. Always request ice-cold plasma ammonia and process within 15 minutes. •      Do not anchor on one diagnosis: a GCS falling despite BZD loading must prompt urgent reassessment for HE, Wernicke's encephalopathy, or hypoglycaemia. •      The CIWA-Ar was not validated in patients with hepatic encephalopathy — its scores may be falsely elevated in HE and lead to BZD overload. Use it with caution and clinical context.

 

4. Oysters 🦪

🦪  Hidden Gems Most Clinicians Miss •      Wernicke's encephalopathy is a third wheel: the classic triad (ophthalmoplegia, ataxia, confusion) is present in <20% of cases. In any patient with AUD and delirium, give IV thiamine 500 mg TDS for at least 3 days — never wait for the triad, never give dextrose first. •      Spontaneous bacterial peritonitis (SBP) is a silent DT precipitant — it can worsen HE through systemic inflammation while simultaneously masking DT's autonomic features. Always perform a diagnostic paracentesis in the cirrhotic patient presenting with altered consciousness, even without abdominal pain. •      Hyponatraemia in cirrhosis blunts the hyperexcitability of withdrawal — DT features may be attenuated in patients with Na <125 mmol/L, leading to false reassurance. Do not lower the CIWA-Ar threshold based on sedate appearance. •      Phenobarbital may be the unsung hero of the mixed state: unlike BZDs, it provides GABAergic sedation via a distinct receptor site with lower respiratory depression risk in titrated doses, and does not disinhibit hepatic encephalopathy as dramatically. •      Alcohol use disorder predisposes to hypoglycaemia through inhibition of gluconeogenesis — always check glucose at presentation and hourly in the first 6 hours. Hypoglycaemia alone can cause agitation and tremor indistinguishable from DT.

 

5. Clinical Hacks & Tips ⚡

⚡  Practical Shortcuts from Master Clinicians •      The '3+3 Rule' for initial DT management: give 3 mg IV lorazepam (or diazepam 10 mg) every 5–10 minutes, up to 3 doses, monitoring respiratory rate — if still agitated after 9 mg lorazepam, move to ICU-level care and consider phenobarbital. •      Use propofol infusion in ventilated patients with refractory DT + HE: it provides GABAergic sedation, does not worsen ammonia, and allows titration without cumulative BZD loading. •      The 'CIWA clock' trick: restart the 24-hour CIWA-Ar clock whenever scores rise >10 — prolonged or relapsing courses predict complicated withdrawal needing HDU escalation. •      In the mixed state, target mild sedation (RASS -1 to 0) rather than deep sedation — over-sedation worsens HE while under-sedation risks DT seizures. •      Ask nursing staff about the 'quiet period' — a window of relative calm between alcohol seizures and DT is characteristic of AWS; absence of this window should raise suspicion for an alternative or additional diagnosis. •      Lactulose works best when it produces 2–3 soft stools per day — less is constipation (worsening HE), more is diarrhoea (electrolyte disaster). Titrate, not simply prescribe.

 

6. State-of-the-Art Updates

Symptom-triggered vs fixed-schedule BZD dosing: A pivotal RCT demonstrated that symptom-triggered lorazepam (guided by CIWA-Ar ≥8) significantly reduces total BZD dose and duration of treatment compared with fixed-schedule dosing without increasing complication rates. This is now standard of care — avoid fixed 4-hourly BZD regimens unless the patient cannot be reliably assessed.

Alpha-2 agonists as BZD-sparing adjuncts: Dexmedetomidine and clonidine are increasingly used to blunt sympathetic hyperactivation in DT, reducing BZD requirements without directly suppressing respiration. Dexmedetomidine is particularly useful in ICU-level DT but does not prevent seizures — it must never replace BZDs as monotherapy.

Rifaximin has transformed outpatient HE: Added to lactulose, rifaximin reduces recurrence of overt HE by >50% and is now guideline-recommended (AASLD/EASL 2014) for secondary prevention. In the inpatient mixed state, it can be started once the patient can swallow, but it does not replace lactulose acutely.

Microbiome modulation and LOLA (L-ornithine L-aspartate): Emerging evidence suggests LOLA reduces ammonia and improves HE grade compared with placebo, and may be particularly useful in HE patients who cannot tolerate lactulose. It is not yet universally guideline-endorsed but is gaining traction in European hepatology practice.

Fecal microbiota transplant (FMT) in HE: Early trials show benefit in recurrent HE refractory to standard therapy, and a landmark RCT by Bajaj et al. demonstrated cognitive and microbiome improvements post-FMT. This remains investigational but represents a genuine paradigm shift in understanding HE as a gut-brain axis disorder.

 

7. Diagnostic Nuances

History

Establish the exact time of last alcoholic drink — this single datum transforms risk stratification. Obtain collateral history from a reliable source. Ask specifically about prior episodes of DT or alcohol withdrawal seizures — "kindling" means each successive withdrawal episode may be more severe. Enquire about dietary intake, as prolonged starvation in alcoholism accelerates refeeding syndrome risk and Wernicke's.

Examination

The neurological examination should be meticulous and repeated. Pupillary dilation favours DT (sympathetic storm); miosis raises concern for opiate use, and normal-to-small pupils are more consistent with HE. The "liver flap" (asterixis) is best elicited with eyes closed, arms extended, and wrists maximally dorsiflexed — a negative test for 15 seconds provides reasonable exclusion. Check for nystagmus and ophthalmoplegia (Wernicke's); hepatic foeter (a sweetish musty breath) in HE; and parotid enlargement and Dupuytren's contracture as stigmata of chronic AUD.

Investigations

Beyond routine bloods, order: EEG — triphasic waves are characteristic of HE; low-voltage fast activity with theta waves predominates in DT. CT head should be performed early if there is focal neurology, head injury concern, or failure to improve. Ammonia (ice-cold plasma) is useful as a trend rather than absolute — a rising ammonia in a deteriorating patient is actionable. Procalcitonin and blood cultures are mandatory; infection is the most common HE precipitant and may simulate autonomic features of DT.

 

8. Management Intricacies

The Non-Negotiables — First Hour

Every patient with suspected DT, HE, or mixed state requires: (1) IV access and continuous monitoring; (2) blood glucose — treat hypoglycaemia immediately with 50% dextrose but only after thiamine; (3) thiamine 500 mg IV TDS — this is the single most important pharmacological intervention in AUD-related neurology; (4) IV fluids — normal saline first-line (avoid dextrose-containing fluids until glucose checked and thiamine given); (5) electrolyte correction — hypokalaemia, hypomagnesaemia, and hypophosphataemia are universal and perpetuate both DT and HE.

Treating Pure DT

Benzodiazepines remain first-line. IV lorazepam 2–4 mg every 5–10 minutes (symptom-triggered) is preferred in severe DT for its predictable pharmacokinetics. Diazepam (10–20 mg IV) exploits its long-acting active metabolites (desmethyldiazepam) for smoother blood levels but accumulates dangerously in hepatic failure — avoid diazepam in decompensated cirrhosis. In refractory DT (CIWA-Ar >20 despite 40 mg diazepam equivalent), use phenobarbital 130–260 mg IV with close respiratory monitoring, or intubate and use propofol infusion. Add dexmedetomidine 0.2–1.4 mcg/kg/h as an adjunct to reduce BZD requirements. Beta-blockers (propranolol, atenolol) blunt tachycardia but do not prevent seizures and should never be used as monotherapy.

Treating Pure HE

Identify and reverse the precipitant — this is as important as any drug. Common triggers (use the mnemonic TIPS: Toxins/drugs, Infection, Porto-systemic shunt, Spontaneous bleeding) should be systematically excluded. Lactulose 30–45 mL every 1–2 hours until 2–3 stools per day, then titrate. Rifaximin 550 mg BD for recurrence prevention. Correct protein malnutrition — do not restrict dietary protein; current EASL guidelines recommend 1.2–1.5 g/kg/day protein. Branched-chain amino acids (BCAAs) may be supplementary in those intolerant to standard protein. Zinc supplementation (220 mg BD) is underused but has trial evidence in HE.

The Mixed State — A Structured Protocol

Step 1: Treat the life-threatening condition first. If CIWA-Ar >20 with autonomic storm — treat DT first with lorazepam (preferred over diazepam in liver disease), using the lowest effective dose.

Step 2: Simultaneously initiate lactulose via NG tube if the patient is obtunded and cannot swallow. Avoid fleet enemas as first-line — they are useful in acute high-ammonia HE but cause electrolyte disturbance.

Step 3: When BZD requirement remains high (>20 mg diazepam equivalent in 24 h) in a patient with decompensated liver disease, transition to phenobarbital — it has less ammonia generation and less respiratory depression at therapeutic doses than escalating BZDs.

Step 4: Target RASS -1 to 0 (lightly sedated, arousable). Deeper sedation worsens HE and delays assessment. Haloperidol 2.5–5 mg IV/IM may be used for agitation not responsive to BZDs but carries QTc prolongation risk — check ECG first.

 

9. When to Escalate / When to Watch

🔴  Escalate to HDU/ICU — Act Now •      Recurrent seizures (≥2 in 6 hours) or status epilepticus •      CIWA-Ar >20 despite ≥40 mg diazepam equivalent in 4 hours •      Respiratory depression (RR <10) or SpO2 <92% in a spontaneously breathing patient on BZDs •      GCS ≤10 or rapidly declining consciousness •      Haemodynamic instability: SBP <90 mmHg or requiring vasopressors •      Acute liver failure superimposed on chronic disease (INR >2.5 + AKI + encephalopathy) — transplant evaluation pathway

 

🟢  Safe to Monitor on a Monitored Ward •      CIWA-Ar 8–15, responding to PRN lorazepam, no seizures •      HE Grade I–II with a clearly identified and addressable precipitant •      Stable haemodynamics, no respiratory compromise, electrolytes corrected •      Patient arousable, protecting airway, tolerating oral lactulose •      Hourly nursing observations with clear escalation triggers documented

 

10. Summary: The DRINK Mnemonic & Comparison Table

The DRINK Mnemonic — your bedside framework for every alcohol-related delirium:

 

Letter	Stands For	Clinical Action
D	Drinking history & Duration	Last drink time, quantity, prior DT/seizures
R	Rule out HE first	LFTs, ammonia, clinical flap — before loading BZDs
I	Investigate triggers	Infection, GI bleed, drugs, electrolytes, glucose
N	Neuro signs	Asterixis = HE; coarse tremor = DT; both = mixed
K	CIWA-Ar scoring	Score every 4–8 h; symptom-triggered dosing preferred
T	Thiamine — always first	500 mg IV TDS × 3 days before any dextrose

 

Differentiation at a Glance

Feature	Delirium Tremens (DT)	Hepatic Encephalopathy (HE)	Mixed (DT + HE)
Onset	12–72 h after last drink	Insidious or precipitant-driven	Variable; overlap possible
Autonomic	Prominent (diaphoresis, tachycardia, hypertension)	Mild or absent	Prominent (DT drives autonomic)
Tremor	Coarse, whole-body	Asterixis (flap)	Both may coexist
Fever	Common (low-grade to 39°C)	Suggests sepsis trigger	Present; exclude infection
Seizures	Yes (early, tonic-clonic)	Rare; suggests other cause	Risk amplified
Pupils	Dilated, reactive	Normal to small	May be dilated
EEG	Low-voltage fast activity	Triphasic waves	May show both patterns
Ammonia	Normal	Elevated (correlates poorly)	Elevated
CIWA-Ar	Scores high	Does not apply	Apply cautiously; titrate carefully
First-Line Rx	Benzodiazepines (IV lorazepam)	Lactulose ± rifaximin	Treat DT first; titrate HE therapy
Key Pitfall	Under-treatment → death	BZDs worsen HE	BZD + HE: titrated phenobarbital safer

 

11. References

1.       DeCarolis DD, Rice KL, Ho L, Willenbring ML, Cassaro S. Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit. Pharmacotherapy. 2007;27(4):510–8.

2.       Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109–13.

3.       Hsieh MJ, Lee WC, Chao YC, Lin MC, Chen CW, Tang YH, et al. Risk factors for alcohol withdrawal delirium: a systematic review and meta-analysis. Drug Alcohol Depend. 2021;224:108753.

4.       Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the AASLD and EASL. Hepatology. 2014;60(2):715–35.

5.       Ferenci P. Hepatic encephalopathy. Gastroenterol Rep. 2017;5(2):138–47.

6.       Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(4):235–46.

7.       Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: a systematic review. Ind Psychiatry J. 2013;22(2):100–8.

8.       Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother. 2011;45(5):649–57.

9.       Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis. Hepatology. 2007;45(6):1348–54.

10.     Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7(9):515–25.

11.     Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353–7.

12.     Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med. 2015;88(3):247–56.

13.     Nanchal R, Subramanian R, Karvellas CJ, Bhupinderjit SR, Balk EM, Bihari S, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU. Crit Care Med. 2020;48(3):e173–91.

14.     Nguyen NH, Khera R, Singh S, Bhatt DL, Bhatt L, Anand BS. Annual burden and costs of hospitalization for alcohol-related liver disease and alcohol withdrawal in the United States. Clin Gastroenterol Hepatol. 2019;17(10):2040–7.

15.     Philips CA, Ahamed R, Augustine P. Hepatic encephalopathy with concurrent alcohol withdrawal: a diagnostic and therapeutic challenge. World J Gastroenterol. 2021;27(3):244–56.

 

 

New-Onset Bleeding in the Critically Ill: A Clinician's Masterclass

A Review Article for Postgraduate Trainees and Practicing Consultants in Internal Medicine and Critical Care

---

Dr Neeraj Manikath , claude.ai

 Keywords: coagulopathy, ICU bleeding, disseminated intravascular coagulation, thrombocytopenia, haemostasis, transfusion

---

Abstract

New-onset bleeding in the intensive care unit (ICU) is simultaneously one of the most common and most treacherous clinical problems encountered by the intensivist. It carries a mortality premium that ranges from 10% in minor mucocutaneous haemorrhage to over 50% in the setting of massive transfusion. Yet, the majority of preventable deaths from ICU haemorrhage arise not from a failure of pharmacological rescue, but from a failure of systematic thinking — misidentifying the mechanism, misjudging the urgency, or mistreating a coagulopathy that was never correctly characterised. This review distils three decades of clinical evidence, bedside wisdom, and state-of-the-art haemostatic science into an actionable, mechanisms-based framework for the clinician at the bedside.

---

1. Introduction: The Patient Who Should Not Have Bled

Case Vignette: A 58-year-old woman with septic shock secondary to community-acquired pneumonia is on Day 4 of her ICU admission. She is mechanically ventilated, receiving noradrenaline at 0.2 mcg/kg/min, broad-spectrum antibiotics, and prophylactic low-molecular-weight heparin. The nursing staff call you at 0200 h because blood is oozing from her endotracheal tube, her arterial line site, and — most alarmingly — the edges of her peripheral IV. Her platelet count yesterday was 110 × 10⁹/L. Today it is 44 × 10⁹/L. Her PT is 22 seconds. Her fibrinogen is 0.9 g/L. She is not on any anticoagulation beyond prophylaxis. What killed her coagulation system overnight?

This vignette — encountered in every busy ICU — represents the quintessential haemostatic catastrophe: consumption coagulopathy driven by uncontrolled sepsis, layered atop a baseline of hepatic dysfunction, nutritional depletion, and iatrogenic factor dilution. It is a story about trajectory, not snapshot. The clinician who sees only today's numbers without understanding yesterday's direction will always be one step behind.

Haemorrhage in the ICU is not a single disease. It is a final common pathway reached by at least a dozen distinct pathophysiological routes: platelet dysfunction from uraemia, factor depletion from dilution, fibrinolysis from hypoperfusion, vitamin K deficiency from malnutrition and antibiotics, heparin accumulation in renal failure, or the rare but devastating heparin-induced thrombocytopaenia with thrombosis (HITT) that paradoxically causes both clotting and bleeding. The clinician who approaches all ICU bleeding with the same empirical formula — "give FFP and platelets" — is practising haematology by reflex rather than by reason.

Epidemiologically, the stakes are unambiguous. Clinically important bleeding — defined as bleeding that causes haemodynamic compromise, requires unplanned transfusion, or leads to procedural interruption — occurs in approximately 5–10% of all ICU admissions. Among patients with sepsis-associated coagulopathy (SAC) or overt DIC, this figure rises to 15–25%. The mortality attributable to haemorrhagic complications, independent of the underlying illness, adds a relative risk of 1.3–1.7 across most ICU cohorts. Yet, haemostatic interventions are among the most frequently misapplied therapies in critical care — transfusion thresholds are too liberal, factor concentrates are underused, and point-of-care viscoelastic testing (VET) remains strikingly underutilised outside of cardiac surgery and trauma centres.

This review will guide you through the architecture of ICU coagulopathy: its mechanisms, its mimics, its mastery.

---

2. Pathophysiology: The Haemostatic System Under Siege

Understanding bleeding in the ICU requires abandoning the antiquated "cascade model" of coagulation and embracing the cell-based model of haemostasis — a framework far more relevant to what actually happens at the endothelial surface during critical illness.

2.1 The Normal Haemostatic Architecture

Haemostasis proceeds in three overlapping phases:

1. Primary haemostasis — Platelet adhesion, activation, and aggregation at the site of vascular injury, forming the primary platelet plug. Governed by von Willebrand factor (vWF), glycoprotein Ib-IX-V, and GPIIb/IIIa.

2. Secondary haemostasis — The coagulation cascade amplifies thrombin generation on the platelet surface, converting fibrinogen to fibrin and stabilising the plug. Tissue factor (TF) on activated monocytes and subendothelial cells initiates extrinsic pathway activation.

3. Fibrinolysis — Plasmin, generated from plasminogen by tPA, dissolves the clot once healing has begun. Regulated by PAI-1 and α2-antiplasmin.

2.2 How Critical Illness Disrupts Each Phase

Phase	ICU Disruption	Clinical Consequence
Primary haemostasis	Uraemic platelet dysfunction, thrombocytopaenia, vWF cleavage by ADAMTS13	Mucocutaneous bleeding, ooze from puncture sites
Secondary haemostasis	Factor dilution, consumption (DIC), liver failure, vitamin K depletion	Prolonged PT/APTT, deep tissue haemorrhage
Fibrinolysis	Hyperfibrinolysis in trauma/liver disease, hypofibrinolysis in sepsis	Uncontrollable surgical bleeding OR paradoxical thrombosis
Endothelium	Loss of thrombomodulin, TF overexpression, glycocalyx shedding	Microvascular thrombosis + haemorrhage simultaneously

2.3 The Sepsis–Coagulation Axis: A Bidirectional Catastrophe

In sepsis, the haemostatic system fails in both directions simultaneously — this is the mechanistic heart of why sepsis-associated coagulopathy (SAC) is so lethal. Tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) drive TF expression on monocytes and endothelial cells → thrombin burst → fibrin deposition in microvasculature → organ failure. Simultaneously, natural anticoagulants — protein C, antithrombin, TFPI — are consumed, downregulated, or cleaved by neutrophil elastase. The result is a system simultaneously "all-on and all-out."

🔑 Key Mechanistic Insight: In sepsis, fibrinogen is consumed BEFORE platelets and factors. A falling fibrinogen in a septic patient is therefore an early warning sign, often preceding overt DIC by 12–24 hours. Serial fibrinogen monitoring is more sensitive than the PT or platelet count for detecting early consumption coagulopathy.

2.4 Dilutional Coagulopathy: The Resuscitation Tax

Every litre of crystalloid administered to a bleeding or shocked patient dilutes clotting factors and platelets. After 1.5 litres of normal saline, the PT begins to prolong. After 2–3 litres, clinically significant coagulopathy sets in. This is not an emergency complication; it is the expected physiological consequence of volume resuscitation. The intensivist who does not anticipate this is perpetually surprised by it.

Modern damage control resuscitation protocols use 1:1:1 ratios of packed red cells: fresh frozen plasma: platelets — precisely to combat dilutional coagulopathy. Yet this paradigm, developed in trauma, is frequently not applied to medical ICU patients with GI bleeding, coagulopathy of liver disease, or post-cardiac surgery haemorrhage, where the same physics applies.

---

3. Diagnostic Nuances: Separating Good from Great Clinicians

3.1 The Clinical History That Most Residents Miss

When confronted with a bleeding ICU patient, the master clinician asks three questions that residents routinely skip:

a) What is the bleeding pattern?

• Mucocutaneous (petechiae, gingival ooze, epistaxis, purpura) → platelet problem (quantitative or qualitative)
• Deep tissue (haematomas, haemarthroses, retroperitoneal collections) → factor deficiency
• Diffuse oozing from ALL puncture sites and surgical wounds → DIC until proven otherwise
• Isolated site bleeding → local cause (wrong vessel puncture, inadequate pressure) — do not over-medicalise

b) What changed in the last 24–48 hours? A sudden drop in haemoglobin without overt external bleeding is occult haemorrhage — retroperitoneal, intrathoracic, or intra-abdominal — until proven otherwise. Do not accept "the lab must have haemolysed the sample."

c) What drugs was the patient given in the last 72 hours?

• Antibiotics → vitamin K depletion (especially cephalosporins, fluoroquinolones)
• Proton pump inhibitors → rarely relevant (good for prophylaxis)
• Heparin — was the dose adjusted for renal function? Anti-Xa level is NOT routinely checked and accumulation is common in AKI
• NSAIDs, aspirin — often omitted from ICU medication reconciliation
• Azole antifungals → dramatically potentiate warfarin via CYP2C9 inhibition

3.2 The Examination That Tells the Story

Beyond the bleeding site, the systematic examination should specifically document:

• Skin: purpura, petechiae, ecchymoses disproportionate to minor trauma
• Mucous membranes: gingival ooze, epistaxis → primary haemostatic failure
• Joints and muscle compartments: feel for tense haematomas
• Surgical drains: character of output — fresh blood (arterial problem), altered blood (venous ooze), or mixed (DIC pattern)
• Catheter sites: oozing from ALL sites simultaneously is the DIC signature sign
• Fundoscopy: retinal haemorrhages in thrombotic microangiopathy (TMA) or extreme thrombocytopaenia
• Abdomen: guarding/rigidity in a coagulopathic patient with dropping Hb = retroperitoneal/visceral haemorrhage until proven otherwise

3.3 Interpreting the Laboratory: The Tests Behind the Tests

🔬 Diagnostic Pearl: The standard coagulation screen (PT, APTT, platelet count, fibrinogen) tells you about plasma, not about whole blood clot formation. These tests are performed at 37°C in ideal laboratory conditions — far removed from the acidaemic, hypothermic, hypocalcaemic milieu of the bleeding ICU patient. A "normal" PT in a patient who is pH 7.2 and temperature 34°C does NOT mean normal coagulation.

The Lethal Triad (acidosis + hypothermia + coagulopathy) mutually amplify each other. Enzymes of the coagulation cascade lose approximately 10% of their activity for every 1°C fall below 37°C. At 33°C, factor activity is reduced by ~40%.

Interpreting the APTT:

• Prolonged APTT alone: heparin effect, factor VIII/IX deficiency (haemophilia), lupus anticoagulant
• Prolonged PT alone: early warfarin effect, isolated factor VII deficiency, mild liver disease
• Both prolonged: DIC, severe liver disease, massive transfusion, supratherapeutic direct oral anticoagulants (DOACs)
• Both normal but patient still bleeding: platelet dysfunction (uraemia, aspirin), hyperfibrinolysis, vascular cause

Fibrinogen: The Underappreciated Vital Sign of Haemostasis Fibrinogen is an acute phase reactant. A "normal" fibrinogen of 2.0 g/L in a systemically inflamed patient who would be expected to have a level of 4–5 g/L represents functional fibrinogen deficiency. This is the most commonly missed laboratory nuance in ICU haemostasis. Target fibrinogen >2.0 g/L for prophylaxis, >2.5 g/L when actively bleeding.

The D-dimer trap: An elevated D-dimer in an ICU patient is almost always present and is diagnostically unhelpful in isolation. D-dimer confirms fibrinolysis has occurred — not DIC, not PE, not DVT specifically. Use it in context, not in isolation.

3.4 Viscoelastic Testing: The Revolution at the Bedside

Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) have transformed haemostatic management in trauma and cardiac surgery by providing a whole-blood, real-time picture of clot formation, strength, and lysis within 15–20 minutes. Key parameters:

Parameter	TEG Equivalent	What It Tells You
Clot Initiation Time (CT/R)	R-time	Prolonged = factor deficiency or anticoagulants → give FFP/PCC
Clot Formation Time (CFT/K)	K-time	Prolonged = fibrinogen/platelet deficiency → give cryoprecipitate
Alpha angle (α)	α angle	Reduced = fibrinogen deficiency → give cryoprecipitate/fibrinogen concentrate
Maximum Amplitude (MA/MCF)	MA	Reduced = platelet dysfunction or deficiency → give platelets
Lysis Index (LY30/ML)	LY30	Elevated = hyperfibrinolysis → give tranexamic acid IMMEDIATELY

⚡ Clinical Hack: In centres without VET, a surrogate for hyperfibrinolysis is the "clot observation test" — mix 2 mL patient blood with 0.1 mL thrombin on a glass slide. If the formed clot lyses within 30–60 minutes, significant fibrinolysis is present. Crude, but life-saving when VET is unavailable.

---

4. Clinical Pearls 🪙

Pearl 1: The Direction of Travel Matters More Than the Number A platelet count of 80 × 10⁹/L is reassuring if it was 40 × 10⁹/L yesterday. It is alarming if it was 220 × 10⁹/L three days ago. ICU haematology is about vectors, not points. Review the trend, not just the current value.

Pearl 2: The Most Common Cause of Thrombocytopaenia in the ICU Is NOT What You Think Most residents reach for "heparin" or "immune thrombocytopaenia" when they see a falling platelet count. The truth? Sepsis is the commonest cause of thrombocytopaenia in the ICU, accounting for 40–60% of cases in most series. Sepsis causes bone marrow suppression, splenic sequestration, platelet consumption by microvascular thrombi, and immune-mediated destruction — all simultaneously.

Pearl 3: You Cannot Correct Coagulopathy in a Bleeding Patient Who Is Still Shocked Haemostatic therapies are physiologically futile in the presence of ongoing hypoperfusion. Lactic acidosis of 8 mmol/L will overwhelm any dose of FFP you give. Fix the shock first. The sequence is: restore perfusion → restore temperature → correct acidosis → then correct coagulopathy.

Pearl 4: The INR Does Not Predict Bleeding Risk in Liver Disease The INR was developed to monitor warfarin therapy — it measures only the procoagulant arm of the coagulation system. In cirrhosis, both procoagulants AND anticoagulants are reduced, often in balance. A patient with cirrhosis and INR 2.5 may have near-normal overall haemostasis (balanced coagulopathy) and carries a far lower bleeding risk than an INR 2.5 warfarin patient. This is why "correcting the INR" with FFP before procedures in cirrhotic patients is largely an evidence-free ritual.

Pearl 5: Protamine for Heparin — Dose It Precisely or Don't Use It Excess protamine is itself anticoagulant — it inhibits platelet function and can cause paradoxical bleeding. The dose is 1 mg protamine per 100 units of unfractionated heparin administered in the preceding 4 hours. Do not give more. Do not give it empirically without knowing the heparin dose.

Pearl 6: Recombinant Factor VIIa is a Last Resort, Not a Rescue Drug rFVIIa (NovoSeven) has been aggressively marketed and irrationally used in ICU bleeding. Outside of haemophilia with inhibitors and a few surgical contexts, its evidence base for ICU bleeding is weak. It increases thromboembolic events by ~10% and does not reduce mortality. Reserve it for truly refractory life-threatening haemorrhage where all other options have been exhausted.

---

5. Oysters 🦪 — Hidden Gems Most Clinicians Miss

Oyster 1: Acquired von Willebrand Syndrome in Critical Illness Continuous-flow LVAD patients, severe aortic stenosis, and ECMO circuits destroy high-molecular-weight vWF multimers through shear stress. The result is an acquired von Willebrand syndrome (AVWS) that perfectly mimics platelet dysfunction. These patients bleed from mucocutaneous sites (gut, nose, skin), have a prolonged PFA-100 but normal vWF antigen, and do not respond to platelets or FFP. Treatment is desmopressin (DDAVP), vWF concentrate, or removal of the offending shear force. This diagnosis is missed in virtually every ICU that doesn't specifically look for it.

Oyster 2: Supratherapeutic Heparin Effect from Renal Failure — The Silent Accumulator Low-molecular-weight heparins (LMWH) are renally cleared. In a patient with AKI, prophylactic enoxaparin 40 mg once daily may accumulate to therapeutic or supratherapeutic anti-Xa levels within 3–5 days. Routine anti-Xa monitoring is not standard of care in most units — yet the haemorrhagic consequences are severe. In any ICU patient with AKI and unexplained bleeding on prophylactic LMWH, check the anti-Xa level (target: 0.2–0.4 IU/mL for prophylaxis). Consider switching to UFH (renal failure-safe, reversed by protamine) or fondaparinux avoidance in eGFR <30 mL/min.

Oyster 3: Hypofibrinolysis — The Other Side of the DIC Coin While hyperfibrinolysis is well-recognised, the opposite state — hypofibrinolysis — is equally deadly and equally ignored. In late-phase sepsis, PAI-1 levels rise dramatically, shutting down fibrinolysis and causing microvascular fibrin deposition. These patients develop multi-organ failure not from bleeding, but from microvascular thrombosis. Paradoxically, their coagulation tests may be "improving" (fibrinogen rising, PT shortening) while their kidneys and liver are being destroyed by microthrombi. TEG/ROTEM with fibrinolytic profiles can detect this; standard coagulation tests cannot.

Oyster 4: The Platelet Count Does Not Tell You What Platelets Are Doing A platelet count of 150 × 10⁹/L in a patient with uraemia, post-cardiopulmonary bypass, or on aspirin/clopidogrel may be haemostatically equivalent to a count of 30 × 10⁹/L in a normal individual. Conversely, patients with essential thrombocythaemia may have counts of 1000 × 10⁹/L with completely dysfunctional platelets. PFA-100 closure time or TEG maximum amplitude (MA) are far better surrogates of platelet function than the count itself.

Oyster 5: Citrate Anticoagulation in CRRT Can Cause Systemic Hypocalcaemia and Bleeding Patients on continuous renal replacement therapy (CRRT) using regional citrate anticoagulation (RCA) are at risk of citrate accumulation — particularly in liver failure, where citrate metabolism is impaired. Citrate chelates ionised calcium. Systemic hypocalcaemia (ionised Ca²⁺ <1.0 mmol/L) causes platelet dysfunction and impaired coagulation factor activity — a perfectly correctable cause of ICU bleeding that is found only if the ionised calcium is actually measured. The clue: a high total calcium with low ionised calcium ratio (>2.5) is pathognomonic of citrate accumulation.

Oyster 6: Stress-Dose Steroids and Adrenal Insufficiency Can Masquerade as Coagulopathy Relative adrenal insufficiency in septic shock causes capillary fragility and poor vascular responsiveness to haemostatic therapies. A patient who bleeds refractory to all haemostatic interventions but whose bleeding resolves dramatically after hydrocortisone 200 mg/day has adrenal insufficiency until proven otherwise. Vasopressin 0.04 units/min has a direct haemostatic effect at the V1 receptor on vascular smooth muscle — use it not just for vasopressor support but as a haemostatic adjunct.

---

6. Clinical Hacks & Tips ⚡

Hack 1: The "Fibrinogen First" Rule In any actively bleeding ICU patient, give fibrinogen concentrate (4 g IV) or cryoprecipitate (10 units) before anything else — before FFP, before platelets. Fibrinogen is the substrate of clot formation. Without it, nothing else works. This is the single most evidence-based shift in contemporary haemostatic resuscitation.

Hack 2: The 4T Score — Use It Every Time You See a Dropping Platelet Count on Heparin HIT (heparin-induced thrombocytopaenia) occurs in 0.5–5% of patients on UFH and is catastrophic if missed. Calculate the 4T score mentally at every encounter with unexplained thrombocytopaenia:

Component	2 points	1 point	0 points
Thrombocytopaenia	>50% fall to nadir ≥20	30–50% fall OR nadir 10–19	<30% fall OR nadir <10
Timing of fall	Days 5–10 or ≤1 day if prior heparin exposure	>10 days OR timing unclear	<4 days without prior exposure
Thrombosis or other sequelae	New thrombosis, skin necrosis	Progressive/recurrent thrombosis	None
oTher cause of thrombocytopaenia	None apparent	Possible	Definite other cause

Score ≥6 = high probability HIT → stop ALL heparin including flushes → start argatroban or fondaparinux → send anti-PF4 antibody assay.

⚡ Critical Hack: HIT patients MUST NOT receive warfarin until the platelet count has recovered to >150 × 10⁹/L. Starting warfarin in active HIT causes catastrophic skin necrosis from protein C depletion. This is a high-stakes pitfall that kills patients.

Hack 3: The MTP Activation Trigger — Don't Wait for Lab Results In massive haemorrhage (>1 blood volume in 24 hours, or >50% blood volume in 3 hours), activate the Massive Transfusion Protocol (MTP) based on clinical assessment — NOT laboratory values. By the time the labs come back, the patient is further behind. Use the ABC Score (Assessment of Blood Consumption): ≥2 of: penetrating mechanism, systolic BP ≤90 mmHg, HR ≥120 bpm, positive FAST — trigger MTP immediately.

Hack 4: Four-Factor PCC (Prothrombin Complex Concentrate) Beats FFP in Urgent Reversal For warfarin reversal in life-threatening haemorrhage, 4F-PCC (Beriplex, Octaplex) achieves complete reversal within 15 minutes, versus 6–12 hours for vitamin K alone and 30–60 minutes for FFP. The dose is 25–50 IU/kg depending on INR. It requires no blood group matching, no thawing, and delivers a tiny volume (20–40 mL vs 1–1.5 L for FFP). In 2024, 4F-PCC is the standard of care for urgent anticoagulation reversal — yet FFP remains the default in many centres, purely out of inertia.

Hack 5: Tranexamic Acid — Timing Is Everything The evidence from CRASH-2 (trauma) and WOMAN (postpartum haemorrhage) is unambiguous: tranexamic acid (TXA) saves lives when given within 3 hours of haemorrhage onset. Beyond 3 hours, it may increase the risk of thromboembolism without mortality benefit. TXA dose: 1 g IV over 10 minutes, repeated after 30 minutes if bleeding continues. In ICU patients with suspected hyperfibrinolysis (TEG LY30 >7.5%), give TXA regardless of aetiology.

Hack 6: The Calcium Imperative Ionised hypocalcaemia is the most reversible, most ignored haemostatic defect in massive transfusion. Citrate in blood products chelates ionised calcium. After 4–6 units of packed red cells, most patients develop clinically significant hypocalcaemia. Supplement with 10 mL 10% calcium gluconate IV after every 4 units of blood product, or target ionised Ca²⁺ >1.1 mmol/L. This is not optional — it is a core component of damage control resuscitation.

---

7. The Differential Diagnosis Framework: A Structured Approach

When you face a bleeding ICU patient, run through this mental checklist in order:

Step 1 — Is This a LOCAL or SYSTEMIC Problem?

Oozing from a single site (drain, wound, catheter) is usually local — surgical haemostasis issue. Bleeding from multiple sites simultaneously (arterial line AND ET tube AND peripheral IV AND urine) is systemic coagulopathy. Do not treat local bleeding with systemic haemostatic agents.

Step 2 — What Is the PLATELET Situation?

• Count <10 × 10⁹/L → transfuse regardless of bleeding status (spontaneous intracranial bleeding risk)
• Count 10–50 × 10⁹/L + active bleeding → transfuse to >50 × 10⁹/L
• Count >50 × 10⁹/L + bleeding → platelet function, not count, is the problem (uraemia, drugs, AVWS)

Step 3 — What Is the COAGULATION Factor Situation?

• INR >1.5 + APTT >1.5× normal + active bleeding → give fibrinogen concentrate FIRST, then FFP or 4F-PCC
• Isolated APTT prolongation → heparin effect? Factor deficiency? Lupus anticoagulant?
• Isolated PT prolongation → early liver disease, warfarin, vitamin K deficiency

Step 4 — Is There FIBRINOLYSIS?

• Clinical: wounds ooze blood that won't clot; clot forms and dissolves
• TEG: LY30 >7.5% or CL30 >15%
• Lab: rapidly falling fibrinogen despite fibrinogen replacement
• Treatment: TXA 1 g IV immediately

Step 5 — Is There a REVERSIBLE DRUG or TOXIN Cause?

• Warfarin → Vitamin K 10 mg IV + 4F-PCC
• UFH → Protamine (1 mg per 100 units)
• LMWH → Protamine (partial reversal, 60–80%)
• DOACs → Idarucizumab (dabigatran), Andexanet alfa (factor Xa inhibitors)
• Thrombolytics → TXA + cryoprecipitate + FFP

---

8. Management Intricacies: Drug Choices, Doses, Timing, Pitfalls

8.1 Blood Products — The Evidence Has Shifted

Fresh Frozen Plasma (FFP):

• Contains ALL coagulation factors at approximately 1 unit/mL concentration
• Dose: 15–20 mL/kg for significant coagulopathy (typically 4–6 units)
• Pitfall: Contains citrate and must be ABO compatible. Takes 20–30 minutes to thaw. Volume overload in cardiac failure. Poor choice for urgent reversal.
• Modern indication: Primarily within 1:1:1 massive transfusion protocol or when specific concentrates are unavailable.

Cryoprecipitate:

• Rich in fibrinogen (10× concentration of FFP), factor VIII, vWF, factor XIII
• Dose: 10 units (raises fibrinogen by ~1 g/L in a 70 kg adult)
• When to use: Fibrinogen <2.0 g/L with active bleeding; fibrinogen <1.5 g/L prophylactically in high-risk patients.
• Better alternative: Fibrinogen concentrate (Haemocomplettan, RiaSTAP) — 4 g raises fibrinogen by ~1 g/L with smaller volume, no thawing, pathogen-reduced.

Platelet Concentrates:

• 1 adult therapeutic dose (ATD) raises count by ~30 × 10⁹/L in a non-refractory patient
• Pitfalls: ABO/Rh compatibility matters. Refractoriness (failure to increment) suggests HLA antibodies, consumption, or splenic sequestration. CMV-negative products for immunocompromised patients.
• Do not transfuse solely for a low platelet count without bleeding in sepsis (TOPIC trial: no benefit, possible harm).

8.2 Haemostatic Agents — Indications Clarified

Tranexamic Acid (TXA):

• Mechanism: competitive inhibitor of plasminogen → antifibrinolytic
• Dose: 1 g IV over 10 min, may repeat once after 30 min
• Evidence: CRASH-2, CRASH-3, WOMAN trials — proven mortality benefit in trauma, PPH; reasonable evidence for GI bleeding
• Caution: Avoid if history of seizures (high doses lower seizure threshold). Contraindicated in haematuria from upper tract source (ureteric obstruction risk).

Desmopressin (DDAVP):

• Mechanism: releases vWF and factor VIII from endothelial Weibel-Palade bodies
• Dose: 0.3 mcg/kg IV over 30 min
• When to use: Platelet dysfunction (uraemia, aspirin effect, post-bypass), type 1 vWD, mild haemophilia A
• Pitfall: Tachyphylaxis occurs after 2–3 doses (stores depleted). Causes dilutional hyponatraemia — restrict free water for 24 h after each dose. Avoid in cardiovascular disease.

4-Factor Prothrombin Complex Concentrate (4F-PCC):

• Contains factors II, VII, IX, X + proteins C and S
• Dose: 25–50 IU/kg (INR-guided), maximum 5000 IU
• Advantage: Rapid, small volume, no blood group matching, no thawing
• Caution: Risk of thrombosis (particularly in HIT, HITT, or hypercoagulable states). Do not use for prophylactic INR "correction."

Recombinant Factor VIIa (rFVIIa):

• Dose: 90 mcg/kg IV (haemophilia); 20–30 mcg/kg in "off-label" ICU use
• Narrow indications: Haemophilia A/B with inhibitors, acquired haemophilia A, Glanzmann thrombasthenia, refractory post-partum haemorrhage
• Evidence gaps: Does NOT improve mortality in ICU bleeding outside these indications; increases arterial thromboembolism by ~10% (RR 1.45, 95% CI 1.02–2.05 in meta-analyses)

8.3 Reversal Agents for Anticoagulants

Drug	Reversal Agent	Dose	Onset
Warfarin (urgent)	4F-PCC + Vitamin K 10 mg IV	25–50 IU/kg	15 min
Warfarin (non-urgent)	Vitamin K 5–10 mg IV		6–12 h
UFH	Protamine sulfate	1 mg/100 units heparin	5 min
LMWH (<8 h ago)	Protamine sulfate	1 mg/100 anti-Xa units	Partial (60%)
Dabigatran	Idarucizumab (Praxbind)	5 g IV (2 × 2.5 g)	Minutes
Rivaroxaban/Apixaban	Andexanet alfa	Weight/dose-adjusted	2 min
Fondaparinux	rFVIIa (off-label)	20–30 mcg/kg	Limited evidence

---

9. State-of-the-Art Updates: Evidence Changing Practice

9.1 Viscoelastic-Guided Haemostatic Therapy: Now Level 1 Evidence in Trauma

The ITACTIC trial (2020) and multiple systematic reviews have demonstrated that VET-guided transfusion reduces blood product usage, reduces allogeneic transfusion exposure, and in some studies reduces mortality versus conventional coagulation test-guided therapy. ROTEM/TEG algorithms have now been incorporated into the European Trauma Guidelines (2023, 7th edition) as the primary haemostatic monitoring tool. Extension of this approach to medical ICU coagulopathy is an active area of investigation.

9.2 Sepsis-Associated Coagulopathy Scoring and the ISTH DIC Score

The ISTH overt DIC score (platelets, PT, fibrinogen, D-dimer) has become the clinical standard for DIC diagnosis. A score ≥5 = overt DIC. The Japanese Association for Acute Medicine (JAAM) DIC score adds SIRS criteria and is more sensitive in sepsis. Recent studies (SCARLET trial, 2019) investigated recombinant thrombomodulin for sepsis-associated DIC — though SCARLET did not achieve its primary endpoint (28-day mortality), post-hoc analyses suggest benefit in the subgroup with coagulopathy but NOT thrombocytopaenia. The story is not closed.

9.3 Fibrinogen Concentrate vs. Cryoprecipitate: The FIBRES Trial

The landmark FIBRES trial (NEJM, 2019) — 735 cardiac surgery patients — demonstrated non-inferiority of fibrinogen concentrate to cryoprecipitate for haemostatic efficacy, with fewer units administered and equivalent safety. This trial has accelerated adoption of fibrinogen concentrate as the fibrinogen replacement product of choice in bleeding cardiac surgery patients and is reshaping practice in other ICU contexts.

9.4 The Transfusion Threshold Revisited: TRISS and Beyond

The landmark TRISS trial established that a restrictive transfusion threshold (Hb 70 g/L) is non-inferior to a liberal threshold (90 g/L) in septic shock. The TRICC, TRISS, and TRICS-III trials collectively support a Hb threshold of 70–80 g/L in most ICU patients without active cardiac ischaemia. Transfusing to a Hb >90 g/L is now considered inappropriate in most ICU contexts — it does not improve outcomes and increases transfusion-related complications (TACO, TRALI, immunomodulation).

Exception: Patients with acute coronary syndrome, symptomatic cardiac failure, or neurocritical injury may tolerate a threshold of 80–100 g/L. Individualise; do not protocolise blindly.

9.5 Gut Microbiome and Vitamin K Synthesis: An Emerging Story

Recent metagenomics research has demonstrated that prolonged ICU admission causes profound dysbiosis of the gut microbiome, reducing microbial menaquinone (vitamin K2) synthesis. Combined with reduced oral intake, malabsorption, and broad-spectrum antibiotics (which eliminate vitamin K-producing bacteria), this creates a state of subclinical vitamin K deficiency that is extraordinarily common and almost universally ignored. A 2023 study in Critical Care Medicine found that 68% of ICU patients on day 7 had vitamin K levels below the normal range, and that empirical IV vitamin K supplementation significantly reduced FFP requirements.

9.6 DOAC-Associated ICU Bleeding: A Growing Crisis

Direct oral anticoagulants now account for >60% of anticoagulant prescriptions in many countries. The ICU clinician in 2025 must be fluent in DOAC reversal. Key updates:

• Idarucizumab (dabigatran reversal) is renally cleared — repeat dosing may be needed in severe AKI
• Andexanet alfa (Xa inhibitor reversal) — the 2023 ANNEXA-I trial (NEJM, 2023) confirmed superiority over placebo for intracranial haemorrhage, though concerns about thrombotic rebound persist
• In the absence of specific reversal agents: 4F-PCC 50 IU/kg provides partial reversal of Xa inhibitors and is the emergency bridge until andexanet alfa is available

---

10. When to Escalate / When to Watch

The fundamental question at 0300 h is never "should I do something?" but "what is the WORST THING that will happen if I do nothing for the next 2 hours?"

Escalate Immediately When:

• Haemorrhagic shock (SBP <90, HR >120, lactate rising)
• Bleeding into enclosed space: intracranial, pericardial, retroperitoneal (no room for expansion)
• Airway threatened by bleeding (haemoptysis, oropharyngeal haemorrhage)
• Platelet count <10 × 10⁹/L (risk of spontaneous intracranial bleeding)
• Fibrinogen <1.0 g/L despite replacement (refractory consumption — underlying DIC uncontrolled)
• Signs of organ dysfunction attributable to haemorrhage (rising creatinine, hepatic encephalopathy, ischaemic ECG changes)
• Failure to respond to first-line haemostatic therapy within 30–60 minutes — reassess diagnosis

Safe to Monitor When:

• Stable haemodynamics, haemoglobin stable after initial transfusion
• Bleeding confined to a single non-critical site (peripheral IV ooze, minor epistaxis) without coagulopathy
• Platelet count 50–100 × 10⁹/L with stable trend, no active bleeding
• INR 1.5–2.0 without active bleeding (prophylactic correction is evidence-free in most contexts)
• Post-procedural ooze responding to local pressure within 15–20 minutes

The "Watch and Worry" Zone — Mandatory Reassessment in 2–4 Hours:

• Platelet count 20–50 × 10⁹/L with stable bleeding pattern
• Fibrinogen 1.0–1.5 g/L on replacement — is the DIC being controlled?
• Haemoglobin dropping 10–20 g/L per 12 hours without obvious source
• Any patient in whom the primary diagnosis driving the coagulopathy (sepsis, DIC, liver failure) has not yet been controlled

---

11. A Memorable Summary: The BLEED Framework

🩸 B — Bleeding Pattern (local vs. systemic; mucocutaneous vs. deep tissue) 🔬 L — Laboratory Trend (direction of PT, platelets, fibrinogen — not just the number) ⚡ E — Eliminate Reversible Causes (drugs, temperature, acidosis, calcium, HIT, DOAC) 🩹 E — Escalate Fibrinogen FIRST (cryoprecipitate/fibrinogen concentrate before FFP) 💊 D — Definitive Treatment of the Underlying Cause (you cannot haemostatically resuscitate a patient whose sepsis/liver failure/DIC is uncontrolled)

---

Summary Table: ICU Bleeding — Pattern, Mechanism, and Management

Clinical Pattern	Most Likely Mechanism	First-Line Action	Pitfall to Avoid
Ooze from all puncture sites	DIC	Fibrinogen concentrate + treat cause	Giving FFP without fibrinogen first
Isolated thrombocytopaenia on heparin	HIT	4T score → stop heparin → argatroban	Starting warfarin in active HIT
Prolonged APTT, normal PT	UFH accumulation in AKI	Check anti-Xa; consider protamine	Assuming therapeutic heparin is safe in AKI
Bleeding + cirrhosis, INR 2.5	Balanced coagulopathy (not true coagulopathy)	Treat precipitant; TEG-guided therapy	Reflexive FFP for INR without active bleeding
GI bleeding + antiplatelet drugs	Platelet dysfunction	DDAVP 0.3 mcg/kg + PPI	Transfusing platelets before DDAVP trial
Trauma + haemorrhagic shock	Acute traumatic coagulopathy + hyperfibrinolysis	TXA within 3 h + 1:1:1 MTP	Delaying TXA for labs to return
Post-cardiac surgery ooze	Platelet dysfunction + heparin effect	Protamine; TEG-guided; DDAVP	Over-protaminating (excess protamine = anticoagulant)
LVAD patient with GI bleeding	Acquired von Willebrand syndrome	DDAVP; consider device speed reduction	Transfusing platelets (ineffective in AVWS)
CRRT citrate + bleeding	Citrate toxicity → hypocalcaemia	Ionised calcium measurement; calcium supplementation	Missing hypocalcaemia in a "coagulopathic" patient

---

12. References

1. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845–854.

2. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370(9):847–859.

3. Collaborators C-T. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). Lancet. 2010;376(9734):23–32.

4. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023;27(1):80.

5. Curry N, Rourke C, Davenport R, et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. Br J Anaesth. 2015;115(1):76–83.

6. Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322(20):1966–1976.

7. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma (PROPPR). JAMA. 2015;313(5):471–482.

8. Mazzeffi M, Greenfield RA, Tanaka KA. Viscoelastic haemostatic testing in major trauma and cardiac surgery: practical aspects of TEG and ROTEM. Anaesthesia. 2022;77(Suppl 1):42–52.

9. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care (TRICC). N Engl J Med. 1999;340(6):409–417.

10. Vincent JL, Sakr Y, Sprung C, et al. Are blood transfusions associated with greater mortality rates? Anesthesiology. 2008;108(1):31–39.

11. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.

12. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–204.

13. Faraoni D, Tanaka KA, Donahue BS, et al. Perioperative considerations for the patient with haemophilia A or B undergoing surgery. Semin Thromb Hemost. 2019;45(8):810–821.

14. Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol. 2019;41(Suppl 1):15–25.

15. Milling TJ Jr, Kaatz S. Preclinical and clinical data for factor Xa and "universal" reversal agents. Am J Emerg Med. 2016;34(11S):39–45.

---

Disclosure: The author declares no conflicts of interest relevant to this article. This review represents the synthesis of current evidence and clinical experience and should not replace institutional protocols or individual clinical judgement. Evidence-based medicine is a foundation, not a ceiling.

 Word count: ~5200